MEK1/2 inhibitors reverse acute vascular occlusion in mouse models of sickle cell disease

FASEB Journal

Volumn 30, Issue 3, 2016, Pages 1171-1186

  Zhao, Yulin ^a   Schwartz, Evan A ^a   Palmer, Gregory M ^b   Zennadi, Rahima ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adhesion; Leukocytes; MEK inhibitors; Sickle red cells

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; BAY 869766; CD18 ANTIGEN; CD44V ANTIGEN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; HEMOGLOBIN S; MITOGEN ACTIVATED PROTEIN KINASE KINASE INHIBITOR; PADGEM PROTEIN; RDEA 119; TRAMETINIB; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR; HERMES ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; PROTEIN KINASE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA;

ACUTE VASCULAR OCCLUSION; ADHERENT CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL OCCLUSION; CONTROLLED STUDY; ERYTHROCYTE; ERYTHROCYTE ADHESIVENESS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTRAVITAL MICROSCOPY; LEUKOCYTE ADHERENCE; MALE; MOUSE; NEUTROPHIL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; SHEAR STRESS; SICKLE CELL ANEMIA; ANEMIA, SICKLE CELL; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; CELL ADHESION; CELL LINE; DISEASE MODEL; DRUG EFFECTS; ENZYMOLOGY; FEMALE; LEUKOCYTE; METABOLISM; NUDE MOUSE; TRANSGENIC MOUSE; VASCULAR DISEASES; VASCULAR ENDOTHELIUM;

ANEMIA, SICKLE CELL; ANIMALS; ANTIGENS, CD44; CELL ADHESION; CELL LINE; DISEASE MODELS, ANIMAL; E-SELECTIN; ENDOTHELIUM, VASCULAR; ERYTHROCYTES; FEMALE; HEMOGLOBIN, SICKLE; HUMANS; INTEGRIN ALPHAVBETA3; LEUKOCYTES; MALE; MAP KINASE KINASE 1; MAP KINASE KINASE 2; MICE; MICE, NUDE; MICE, TRANSGENIC; P-SELECTIN; PROTEIN KINASE INHIBITORS; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR DISEASES;

EID: 84963944133     PISSN: 08926638     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.15-278481     Document Type: Article

References (49)

1. Platt, O. S., Brambilla, D. J., Rosse, W. F., Milner, P. F., Castro, O., Steinberg, M. H., and Klug, P. P. (1994) Mortality in sickle cell disease. Life expectancy and risk factors for early death. N. Engl. J. Med. 330, 1639-1644
2. Hebbel, R. P. (1997) Adhesive interactions of sickle erythrocytes with endothelium. J. Clin. Invest. 100(11, Suppl), S83-S86
3. Turhan, A., Weiss, L. A., Mohandas, N., Coller, B. S., and Frenette, P. S. (2002) Primary role for adherent leukocytes in sickle cell vascular occlusion: a new paradigm. Proc. Natl. Acad. Sci. USA 99, 3047-3051
4. Zennadi, R., Moeller, B. J., Whalen, E. J., Batchvarova, M., Xu, K., Shan, S., Delahunty, M., Dewhirst, M. W., and Telen, M. J. (2007) Epinephrine-induced activation of LW-mediated sickle cell adhesion and vaso-occlusion in vivo. Blood 110, 2708-2717
5. Zennadi, R., Whalen, E. J., Soderblom, E. J., Alexander, S. C., Thompson, J. W., Dubois, L. G., Moseley, M. A., and Telen, M. J. (2012) Erythrocyte plasma membrane-bound ERK1/2 activation promotes ICAM-4-mediated sickle red cell adhesion to endothelium. Blood 119, 1217-1227
6. Cai, K., Qi, D., Hou, X., Wang, O., Chen, J., Deng, B., Qian, L., Liu, X., and Le, Y. (2011) MCP-1 upregulates amylin expression in murine pancreatic b cells through ERK/JNK-AP1 and NF-κB related signaling pathways independent of CCR2. PLoS One 6, e19559
7. Wang, N., Guan, P., Zhang, J. P., Li, Y. Q., Chang, Y. Z., Shi, Z. H., Wang, F. Y., and Chu, L. (2011) Fasudil hydrochloride hydrate, a Rho-kinase inhibitor, suppresses isoproterenol-induced heart failure in rats via JNK and ERK1/2 pathways. J. Cell. Biochem. 112, 1920-1929
8. Zennadi, R. (2014) MEK inhibitors, novel anti-adhesive molecules, reduce sickle red blood cell adhesion in vitro and in vivo, and vasoocclusion in vivo. PLoS One 9, e110306
9. József, L., Khreiss, T., Fournier, A., Chan, J. S., and Filep, J.G. (2002) Extracellular signal-regulated kinase plays an essential role in endothelin-1-induced homotypic adhesion of human neutrophil granulocytes. Br. J. Pharmacol. 135, 1167-1174
10. Kohno, M., and Pouyssegur, J. (2003) Pharmacological inhibitors of the ERK signaling pathway: application as anticancer drugs. Prog. Cell Cycle Res. 5, 219-224
11. Milella, M., Kornblau, S. M., and Andreeff, M. (2003) The mitogenactivated protein kinase signaling module as a therapeutic target in hematologic malignancies. Rev. Clin. Exp. Hematol. 7, 160-190
12. Jo, S. K., Cho, W. Y., Sung, S. A., Kim, H. K., and Won, N. H. (2005) MEK inhibitor, U0126, attenuates cisplatin-induced renal injury by decreasing inflammation and apoptosis. Kidney Int. 67, 458-466
13. Namura, S., Iihara, K., Takami, S., Nagata, I., Kikuchi, H., Matsushita, K., Moskowitz, M. A., Bonventre, J. V., and Alessandrini, A. (2001) Intravenous administration of MEK inhibitor U0126 affords brain protection against forebrain ischemia and focal cerebral ischemia. Proc. Natl. Acad. Sci. USA 98, 11569-11574
14. Zennadi, R., Hines, P.C., DeCastro, L.M., Cartron, J.P., Parise, L.V., and Telen, M. J. (2004) Epinephrine acts through erythroid signaling pathways to activate sickle cell adhesion to endothelium via LW-alphavbeta3 interactions. Blood 104, 3774-3781
15. Zennadi, R., Chien, A., Xu, K., Batchvarova, M., and Telen, M. J. (2008) Sickle red cells induce adhesion of lymphocytes and monocytes to endothelium. Blood 112, 3474-3483
16. Xiao, Y., and Truskey, G. A. (1996) Effect of receptor-ligand affinity on the strength of endothelial cell adhesion. Biophys. J. 71, 2869-2884
17. Levasseur, D.N., Ryan, T.M., Pawlik, K.M., and Townes, T.M.(2003) Correction of a mouse model of sickle cell disease: lentiviral/antisickling beta-globin gene transduction of unmobilized, purified hematopoietic stem cells. Blood 102, 4312-4319
18. Townes, T. M., Ryan, T. M., Behringer, R. R., Palmiter, R. D., and Brinster, R. L. (1989) DNase I super-hypersensitive sites direct high level erythroid expression of human alpha-, beta- and beta s-globin genes in transgenic mice. Prog. Clin. Biol. Res. 316A, 47-61
19. Ryan, T. M., Townes, T.M., Reilly, M. P., Asakura, T., Palmiter, R. D., Brinster, R. L., and Behringer, R. R. (1990) Human sickle hemoglobin in transgenic mice. Science 247, 566-568
20. Chantrathammachart, P., Mackman, N., Sparkenbaugh, E., Wang, J.G., Parise, L. V., Kirchhofer, D., Key, N. S., and Pawlinski, R. (2012) Tissue factor promotes activation of coagulation and inflammation in a mouse model of sickle cell disease. Blood 120, 636-646
21. King, M. R., Bansal, D., Kim, M. B., and Sarelius, I. H. (2004) The effect of hematocrit and leukocyte adherence on flow direction in the microcirculation. Ann. Biomed. Eng. 32, 803-814
22. Chiou, E., and Zennadi, R. (2015) Gas proteins activate p72(Syk) and p60-c-Src tyrosine kinases to mediate sickle red blood cell adhesion to endothelium via LW-αvβ3 and CD44-CD44 interactions. Int. J. Biochem. Cell Biol. 65, 40-51
23. Matsui, N.M., Borsig, L., Rosen, S. D., Yaghmai, M., Varki, A., and Embury, S. H. (2001) P-selectin mediates the adhesion of sickle erythrocytes to the endothelium. Blood 98, 1955-1962
24. Chang, J., Patton, J. T., Sarkar, A., Ernst, B., Magnani, J. L., and Frenette, P. S. (2010) GMI-1070, a novel pan-selectin antagonist, reverses acute vascular occlusions in sickle cell mice. Blood 116, 1779-1786
25. Frenette, P. S., Mayadas, T. N., Rayburn, H., Hynes, R. O., and Wagner, D. D. (1996) Susceptibility to infection and altered hematopoiesis in mice deficient in both P- and E-selectins. Cell 84, 563-574
26. Ishikawa, M., Cooper, D., Arumugam, T. V., Zhang, J.H., Nanda, A., and Granger, D. N. (2004) Platelet-leukocyte-endothelial cell interactions after middle cerebral artery occlusion and reperfusion. J. Cereb. Blood Flow Metab. 24, 907-915
27. Ichioka, S., Sekiya, N., Shibata, M., and Nakatsuka, T. (2007) Alpha V beta3 (alphavbeta3) integrin inhibition reduces leukocyteendothelium interaction in a pressure-induced reperfusion model. Wound Repair Regen. 15, 572-576
28. Gilmartin, A.G., Bleam, M. R., Groy, A., Moss, K. G., Minthorn, E. A., Kulkarni, S.G., Rominger, C. M., Erskine, S., Fisher, K. E., Yang, J., Zappacosta, F., Annan, R., Sutton, D., and Laquerre, S. G. (2011) GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition. Clin. Cancer Res. 17, 989-1000.
29. Iverson, C., Chapman, M. S., Clendeninn, N., Girardet, J., Sheedy, B., Manhard, K., Yeh, L., Miner, J.N., and Quart, B. (2008) The effect of MEK inhibitor RDEA119 on biomarkers in advanced cancer patients in a phase I clinical trial. ASCO-NCI Annual Meeting on Molecular Markers in Cancer (poster #A15) (abstr.)
30. Iverson, C., Larson, G., Lai, C., Yeh, L.T., Dadson, C., Weingarten, P., Appleby, T., Vo, T., Maderna, A., Vernier, J.M., Hamatake, R., Miner, J. N., and Quart, B. (2009) RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer. Cancer Res. 69, 6839-6847
31. Weekes, C. D., Von Hoff, D. D., Adjei, A. A., Leffingwell, D. P., Eckhardt, S.G., Gore, L., Lewis, K.D., Weiss, G. J., Ramanathan, R.K., Dy, G. K., Ma, W.W., Sheedy, B., Iverson, C., Miner, J.N., Shen, Z., Yeh, L. T., Dubowy, R. L., Jeffers, M., Rajagopalan, P., and Clendeninn, N. J. (2013) Multicenter phase I trial of the mitogenactivated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer. Clin. Cancer Res. 19, 1232-1243.
32. Infante, J.R., Fecher, L.A., Falchook, G.S., Nallapareddy, S., Gordon, M. S., Becerra, C., DeMarini, D. J., Cox, D. S., Xu, Y., Morris, S. R., Peddareddigari, V.G., Le, N. T., Hart, L., Bendell, J. C., Eckhardt, G., Kurzrock, R., Flaherty, K., Burris III, H. A., and Messersmith, W. A. (2012) Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. Lancet Oncol. 13, 773-781
33. Kurantsin-Mills, J., Jacobs, H.M., Klug, P. P., and Lessin, L. S. (1987) Flow dynamics of human sickle erythrocytes in the mesenteric microcirculation of the exchange-transfused rat. Microvasc. Res. 34, 152-167
34. Pignatelli, P., De Biase, L., Lenti, L., Tocci, G., Brunelli, A., Cangemi, R., Riondino, S., Grego, S., Volpe, M., and Violi, F. (2005) Tumor necrosis factor-alpha as trigger of platelet activation in patients with heart failure. Blood 106, 1992-1994
35. Li, J., Kim, K., Hahm, E., Molokie, R., Hay, N., Gordeuk, V. R., Du, X., and Cho, J. (2014) Neutrophil AKT2 regulates heterotypic cell-cell interactions during vascular inflammation. J. Clin. Invest. 124, 1483-1496
36. Kaul, D. K., Tsai, H. M., Liu, X. D., Nakada, M. T., Nagel, R. L., and Coller, B. S. (2000) Monoclonal antibodies to alpha Vbeta3 (7E3 and LM609) inhibit sickle red blood cell-endothelium interactions induced by platelet-activating factor. Blood 95, 368-374
37. Lai, H. H., Qiu, C. S., Crock, L. W., Morales, M. E., Ness, T. J., and Gereau IV, R. W. (2011) Activation of spinal extracellular signalregulated kinases (ERK) 1/2 is associated with the development of visceral hyperalgesia of the bladder. Pain 152, 2117-2124
38. Davies, B. R., Logie, A., McKay, J. S., Martin, P., Steele, S., Jenkins, R., Cockerill, M., Cartlidge, S., and Smith, P.D. (2007) AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models. Mol. Cancer Ther. 6, 2209-2219
39. Wang, Z. Q., Wu, D. C., Huang, F. P., and Yang, G. Y. (2004) Inhibition of MEK/ERK 1/2 pathway reduces pro-inflammatory cytokine interleukin-1 expression in focal cerebral ischemia. Brain Res. 996, 55-66
40. Fadlon, E., Vordermeier, S., Pearson, T. C., Mire-Sluis, A. R., Dumonde, D. C., Phillips, J., Fishlock, K., and Brown, K. A. (1998) Blood polymorphonuclear leukocytes from the majority of sickle cell patients in the crisis phase of the disease show enhanced adhesion to vascular endothelium and increased expression of CD64. Blood 91, 266-274
41. Belcher, J. D., Marker, P. H., Weber, J. P., Hebbel, R. P., and Vercellotti, G. M. (2000) Activated monocytes in sickle cell disease: potential role in the activation of vascular endothelium and vasoocclusion. Blood 96, 2451-2459
42. Thompson, H. L., Shiroo, M., and Saklatvala, J. (1993) The chemotactic factor N-formylmethionyl-leucyl-phenylalanine activates microtubule-associated protein 2 (MAP) kinase and a MAP kinase kinase in polymorphonuclear leucocytes. Biochem. J. 290, 483-488
43. Pillinger, M.H., Feoktistov, A. S., Capodici, C., Solitar, B., Levy, J., Oei, T. T., and Philips, M. R. (1996) Mitogen-activated protein kinase in neutrophils and enucleate neutrophil cytoplasts: evidence for regulation of cell-cell adhesion. J. Biol. Chem. 271, 12049-12056
44. Capodici, C., Pillinger, M. H., Han, G., Philips, M. R., and Weissmann, G. (1998) Integrin-dependent homotypic adhesion of neutrophils. Arachidonic acid activates Raf-1/Mek/Erk via a 5-lipoxygenase-dependent pathway. J. Clin. Invest. 102, 165-175
45. Zouki, C., Zhang, S. L., Chan, J. S., and Filep, J. G. (2001) Peroxynitrite induces integrin-dependent adhesion of human neutrophils to endothelial cells via activation of the Raf-1/MEK/Erk pathway. FASEB J. 15, 25-27
46. Gardner, A. M., Vaillancourt, R. R., and Johnson, G. L. (1993) Activation of mitogen-activated protein kinase/extracellular signalregulated kinase kinase by G protein and tyrosine kinase oncoproteins. J. Biol. Chem. 268, 17896-17901
47. Worthen, G. S., Avdi, N., Buhl, A. M., Suzuki, N., and Johnson, G. L. (1994) FMLP activates Ras and Raf in human neutrophils. Potential role in activation of MAP kinase. J. Clin. Invest. 94, 815-823
48. Herrera-García, A., Domínguez-Luis, M., Arce-Franco, M., López-Fernández, J., Feria, M., Barreiro, O., Sánchez-Madrid, F., and Díaz-González, F. (2013) In vivo modulation of the inflammatory response by nonsteroidal antiinflammatory drugrelated compounds that trigger L-selectin shedding. Eur. J. Immunol. 43, 55-64
49. Landsberger, M., Wolff, B., Jantzen, F., Rosenstengel, C., Vogelgesang, D., Staudt, A., Dahm, J. B., and Felix, S. B. (2007) Cerivastatin reduces cytokine-induced surface expression of ICAM-1 via increased shedding in human endothelial cells. Atherosclerosis 190, 43-52